Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test

·       Reauthorization of EUA expands beyond initial

qualitative detection claim

·       CEO to appear on Cheddar News at 6:10pm

tonight, November 17th, 2021

New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – November 17, 2021 – Todos

Medical, Ltd. (OTCQB: TOMDF), a

comprehensive medical diagnostics and related solutions company, today

announced that the United States Food & Drug Administration has

reauthorized the Emergency Use Authorization (EUA) for the cPass neutralizing

antibody test (“cPass”)*. The new indication for cPass now reads:

Qualitative and

semi-quantitative direct detection of total neutralizing antibodies to

SARS-CoV-2 in human serum and dipotassium EDTA plasma. Intended for use as an

aid in identifying individuals with an adaptive immune response to SARS-CoV-2,

indicating recent or prior infection. Emergency use of this test is limited to

authorized laboratories.

Concurrent with this

announcement, the Company announced that CEO Gerald Commissiong is to appear on

Cheddar News at 6:10pm tonight, November 17th, 2021.

For more information, please

visit For more information

on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit

* This test has not been FDA

cleared or approved. This test has been authorized by FDA under an EUA for use

by authorized laboratories. This test has been authorized only for the presence

of total neutralizing antibodies against SARS-CoV-2, not for any other viruses

or pathogens. This test is only authorized for the duration of the declaration

that circumstances exist justifying the authorization of emergency use of in

vitro diagnostics for detection and/or diagnosis of COVID-19 under Section

564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1),

unless the authorization is terminated or revoked sooner.

About Todos Medical Ltd.

Founded in Rehovot, Israel with

offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers

life-saving diagnostic solutions for the early detection of a variety of

cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared

Analyses (TBIA) is a proprietary cancer-screening technology using peripheral

blood analysis that deploys deep examination into cancer’s influence on the immune

system, looking for biochemical changes in blood mononuclear cells and plasma.

Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have

received a CE mark in Europe. Todos recently acquired U.S.-based medical

diagnostics company Provista Diagnostics, Inc. to gain rights to its

Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID

testing and Provista’s proprietary commercial-stage Videssa® breast cancer

blood test.

Todos is also developing blood

tests for the early detection of neurodegenerative disorders, such as

Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test) is a

diagnostic blood test that determines the ability of peripheral blood

lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic

stimulation that induces them to enter the cell cycle. It is believed that

certain diseases, most notably Alzheimer’s disease, are the result of

compromised cellular machinery that leads to aberrant cell cycle re-entry by

neurons, which then leads to apoptosis. LymPro is unique in the use of

peripheral blood lymphocytes as a surrogate for neuronal cell function,

suggesting a common relationship between PBLs and neurons in the brain.

Todos has entered into

distribution agreements with companies to distribute certain novel coronavirus

(COVID-19) test kits. The agreements cover multiple international suppliers of

PCR testing kits and related materials and supplies, as well as antibody

testing kits from multiple manufacturers after completing validation of said

testing kits and supplies in its partner CLIA/CAP certified laboratory in the

United States. Additionally, Todos has entered into a joint venture with NLC

Pharma to pursue the development of diagnostic tests targeting the 3CL protease,

as well as 3CL protease inhibitors that target a fundamental reproductive

mechanism of coronaviruses.

For more information, please


Forward-looking Statements

Certain statements contained in

this press release may constitute forward-looking statements. For example,

forward-looking statements are used when discussing our expected clinical

development programs and clinical trials. These forward-looking statements are

based only on current expectations of management, and are subject to

significant risks and uncertainties that could cause actual results to differ

materially from those described in the forward-looking statements, including

the risks and uncertainties related to the progress, timing, cost, and results

of clinical trials and product development programs; difficulties or delays in

obtaining regulatory approval or patent protection for product candidates;

competition from other biotechnology companies; and our ability to obtain

additional funding required to conduct our research, development and

commercialization activities. In addition, the following factors, among others,

could cause actual results to differ materially from those described in the

forward-looking statements: changes in technology and market requirements;

delays or obstacles in launching our clinical trials; changes in legislation;

inability to timely develop and introduce new technologies, products and

applications; lack of validation of our technology as we progress further and

lack of acceptance of our methods by the scientific community; inability to

retain or attract key employees whose knowledge is essential to the development

of our products; unforeseen scientific difficulties that may develop with our

process; greater cost of final product than anticipated; loss of market share

and pressure on pricing resulting from competition; and laboratory results that

do not translate to equally good results in real settings, all of which could cause

the actual results or performance to differ materially from those contemplated

in such forward-looking statements. Except as otherwise required by law, Todos

Medical does not undertake any obligation to publicly release any revisions to

these forward-looking statements to reflect events or circumstances after the

date hereof or to reflect the occurrence of unanticipated events. For a more

detailed description of the risks and uncertainties affecting Todos Medical,

please refer to its reports filed from time to time with the U.S. Securities

and Exchange Commission.


Corporate and Investor Contact:

Richard Galterio

Todos Medical


Source link

The post Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test first appeared on Smallcaps Daily.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button